Biotechnology News and Research

RSS

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, and Life Technologies Corporation today announced Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays.

2 Apr 2012

TGen to present TNBC study at AACR 2012 annual meeting

Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.

2 Apr 2012

Teva launches generic Avalide and Avapro Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of both Irbesartan and Irbesartan-Hydrochlorothiazide Tablets, the Company's generic versions of Sanofi Aventis' high blood pressure treatments, Avapro and Avalide Tablets.

2 Apr 2012

Diversity of intestinal stem cells is greater than previously thought

Tales from the crypt are supposed to be scary, but new research from Vanderbilt University, the HudsonAlpha Institute for Biotechnology and colleagues shows that crypts can be places of renewal too: intestinal crypts, that is. Intestinal crypts are small areas of the intestine where new cells are formed to continuously renew the digestive tract. By focusing on one protein expressed in our intestines called Lrig1, the researchers have identified a special population of intestinal stem cells that respond to damage and help to prevent cancer.

31 Mar 2012

Clinical findings from Transgenomic's NuclearMitome Test study on nuclear mitochondrial disorders

Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.

31 Mar 2012

Teva introduces generic Provigil

Teva Pharmaceutical Industries Ltd. announces the launch of the authorized generic of Provigil (modafinil).

31 Mar 2012

Cancer cells grow and proliferate more robustly when exposed to human cells

New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.

30 Mar 2012

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology, today announced that Roche has announced positive topline results from its trastuzumab emtansine (T-DM1) EMILIA Phase III trial.

30 Mar 2012

ProImmune introduces Special Assay Service

ProImmune Ltd., a leader in services for understanding immune responses, has launched a new Special Assay Service, providing unique, bespoke immunological assays, based on ProImmune's broad ranging proprietary platform technologies, to meet customers' assay needs.

29 Mar 2012

CRT, EIF create £50M Cancer Research Technology Pioneer Fund

Cancer Research Technology, (CRT) Cancer Research UK's commercial arm, and the European Investment Fund (EIF) have joined together to create a £50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development.

29 Mar 2012

Oncothyreon proposes underwritten public offering of common stock

Oncothyreon Inc. today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.

29 Mar 2012

Southfield Capital acquires majority ownership of BioPharm

Southfield Capital, a private investment firm focused on the lower middle-market, announced today that it has acquired majority ownership of BioPharm Communications.

29 Mar 2012

Regulatory agencies approve plans for e-Therapeutics' ETS2101 phase I trials in cancer

e-Therapeutics plc announces that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company's anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.

29 Mar 2012

EMA grants orphan designations to Ultragenyx UX001, UX003 for treatment of HIBM and MPS 7

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.

29 Mar 2012

Affymetrix' GeneChip technology incorporated into Lineagen's FirstStepDx genetic evaluation service

Affymetrix, Inc. and Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, today announced the companies have signed an agreement to incorporate Affymetrix' GeneChip technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD).

29 Mar 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

Scientists explore number of strategies to prevent anesthesia-induced injury in infants

Recent clinical studies have shown that general anesthesia can be harmful to infants, presenting a dilemma for both doctors and parents. But new research at Wake Forest Baptist Medical Center may point the way to treatment options that protect very young children against the adverse effects of anesthesia.

29 Mar 2012

NEJM publishes results from Amgen's brodalumab Phase 2 trial on plaque psoriasis

Amgen announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine.

29 Mar 2012

MESO-1 device can help in diagnosis and treatment of cancer

A new device designed to more effectively produce DNA samples for genetic testing from slide-mounted tissue samples is better equipped than most models on the market to help in the diagnosis and treatment of cancer.

29 Mar 2012